Lupin Pharmaceuticals Launches Raltegravir Tablets in the U.S. Market

On November 3, 2026, Lupin Limited, a major global player in the pharmaceutical industry, announced the introduction of its Raltegravir Tablets USP, 600 mg in the United States. This launch comes after receiving approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), marking a pivotal entry into the competitive market of HIV treatments.

About the Product

The Raltegravir Tablets, 600 mg, are bioequivalent to the reference listed drug (RLD) Isentress® HD, developed by Merck Sharp & Dohme, LLC. These tablets are indicated for use in conjunction with other antiretroviral medicines to treat adult patients and pediatric patients with HIV-1 infection, specifically those weighing at least 40 kg.

What makes this launch notable is that Lupin is the exclusive first-to-file for this generic version of Raltegravir. This status grants the company a 180-day exclusivity period, which is a significant advantage in the pharmaceutical landscape. The estimated annual sales for the RLD Isentress® HD in the U.S. were reported to be around USD 26 million, indicating a robust potential for Lupin’s version.

The Significance of This Launch

For Lupin, this launch not only diversifies its product portfolio but also strengthens its presence in the U.S. market, where it has been focusing on expanding its offerings in critical therapeutic areas. The company’s strategy revolves around developing a range of generic medications that align with the growing demand for affordable healthcare solutions.

With Raltegravir, Lupin continues to cater to the segment of patients dealing with HIV-1, contributing to the global fight against this virus. By providing a cost-effective alternative to existing treatments, Lupin enhances patient access to essential medicines, which is vital in chronic conditions like HIV/AIDS.

About Lupin Limited

Lupin Limited, headquartered in Mumbai, India, has established itself as a formidable entity in the pharmaceutical sector, operating across various developed and emerging markets. With its products distributed in over 100 markets, it has built a comprehensive portfolio that includes generics, biosimilars, and complex generics. This extensive range allows Lupin to address a variety of health issues spanning cardiology, respiratory diseases, diabetes, gastrointestinal disorders, and women's health.

The company boasts 15 state-of-the-art manufacturing facilities and maintains six research centers, driven by a dedicated workforce of over 26,000 professionals. This infrastructure supports its robust R&D initiatives and ensures high-quality manufacturing processes, thus fostering trust within the healthcare ecosystem.

Commitment to Sustainability and Innovation

In addition to expanding its product range, Lupin is committed to sustainability and innovation within the healthcare sector. The company actively engages in various patient support programs, digital health solutions, and disease management initiatives to improve health outcomes globally. Its focus on sustainability is a core aspect of its business strategy, ensuring that it remains compliant with evolving environmental and social standards.

For those interested in learning more, visit their official website at www.lupin.com or connect with them on LinkedIn.

Conclusion

Lupin's introduction of Raltegravir Tablets in the U.S. marks a significant achievement, not only for the company but also for patients requiring advanced HIV treatment options. With a strong pipeline of generic drugs and an established market presence, Lupin is well-positioned to meet the challenges and demands of the healthcare sector.